Vertex Pharmaceuticals (VRTX) Stock Price, Fundamentals & Analysis

What VRTX does

Vertex Pharmaceuticals (VRTX) is a biotechnology company headquartered in Boston, United States, operating in the Healthcare sector. It develops transformative medicines for serious diseases, with a focus on cystic fibrosis (CF), sickle cell disease (TDT), transfusion-dependent beta thalassemia, and acute pain. Key products include TRIKAFTA/KAFTRIO for CF patients with at least one F508del mutation aged 2 years and older, ALYFTREK for CF patients 6 years and older, SYMDEKO/SYMKEVI for CF patients 6 years and older, ORKAMBI for CF patients 1 year or older, and KALYDECO for patients 1 month and older with CF who have an ivacaftor-responsive mutation.

Key numbers explained

• $516.34 is the current share price, representing the cost to buy one share on the US market.
• The trailing P/E ratio of 30.1 shows how much investors pay per dollar of the company's last 12 months' earnings; a higher number can reflect growth expectations.
• The forward P/E ratio of 25.7 uses expected future earnings, offering a look at how the market values what the company might earn next.
• Earnings per share (trailing 12 months) of $17.16 is the portion of the company's profit allocated to each outstanding share.
• Dividend yield of 0% and 0% of earnings paid out as dividends mean the company currently does not distribute cash to shareholders.
• Beta of 0.32 suggests the stock tends to be less volatile than the overall market, often moving about a third as much as the broad market.
• Market capitalisation of 130.79B USD is the total value of all outstanding shares, placing Vertex among large-cap companies.
• Price change over the last 52 weeks of 36.7% indicates the stock's total return from one year ago to today, including price movement.

Recent news

• Vertex posted positive Phase II data on a kidney disease drug.
• TD Cowen adjusted its price target on Vertex Pharmaceuticals to $550 from $525, maintaining a Buy rating.
• Jefferies adjusted its price target on Vertex Pharmaceuticals to $640 from $633, maintaining a Buy rating.

What to watch

As a Healthcare biotechnology stock, Vertex Pharmaceuticals can be sensitive to clinical trial results, regulatory decisions on new treatments, and broader sector trends. Investors often compare it with peers such as Illumina, Inc. (ILMN), Intuitive Surgical (ISRG), and Thermo Fisher Scientific (TMO) to contextualise its growth and valuation. The company is part of the S&P 500, which means it is a large, widely followed component of the US equity market.